0001628280-26-031739
SEC filingargenx SE reported Q1 2026 financial results with $1.3 billion in global VYVGART net sales, up 63% year-over-year, and profit of $366 million.
argenx delivered exceptional Q1 2026 results with product net sales reaching $1.3 billion, a 63% year-over-year increase primarily from VYVGART across US ($1.107B, +62%), Japan (+111%), and Rest of World (+99%), reflecting 17 consecutive quarters of growth and strong commercial execution in gMG and CIDP. CEO Karen Massey highlighted sustained VYVGART momentum and pipeline potential, including FDA PDUFA on May 10, 2026 for seronegative gMG expansion and positive ADAPT OCULUS data supporting ocular MG sBLA. Operating expenses rose to $919M from $668M, driven by R&D ($443M for efgartigimod, empasiprubart, adimanebart) and SG&A ($355M for commercialization), yet operating profit expanded 183% to $394M with profit margins improving significantly. Cash position strengthened to $4.9B, supporting Vision 2030 ambitions. Key catalysts include empasiprubart EMPASSION topline in Q4 2026 for MMN, ALKIVIA myositis in Q3 2026, and leadership transition with Massey as CEO post-AGM on May 6. These results underscore argenx's FcRn leadership and immunology pipeline advancement amid robust demand.